Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FABP1 | P07148 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514984 | 0.78 | KMT2A (0.38) | ALDH1A1KMT2AMEN1HSD11B1SMN1; SMN2 | |
| SCHEMBL15216504 | 0.78 | KMT2A (0.38) | ALDH1A1KMT2AMEN1HSD11B1SMN1; SMN2 | |
| SCHEMBL1004336 | 0.78 | KMT2A (0.38) | ALDH1A1KMT2AMEN1HSD11B1SMN1; SMN2 | |
| SCHEMBL6153742 | 0.78 | NFE2L2 (0.44) | LMNAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL8012066 | 0.78 | PTGS2 (0.42) | LMNAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL6449477 | 0.77 | KMT2A (0.38) | ALDH1A1KMT2AMEN1HSD11B1SMN1; SMN2 | |
| SCHEMBL7897440 | 0.76 | ALDH1A1 (0.37) | LMNAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL5549224 | 0.74 | ALDH1A1 (0.44) | LMNAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL2799147 | 0.73 | KMT2A (0.36) | LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL13232732 | 0.73 | KMT2A (0.36) | LMNAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1922075-A2 | ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS | Oklahoma Medical Research Foundation (US) | 2008-05-21 | — | — | EP | claimed |
| WO-2007019065-A2 | ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032453-A1 | ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2007-02-08 | — | — | US | claimed |
| US-6569902-B2 | Nitrone inhibition of cancer development | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2003-05-27 | — | — | US | claimed |
| EP-1922075-A2 | ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS | Oklahoma Medical Research Foundation (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007019065-A2 | ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032453-A1 | ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032453-A1 | ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS | MGMT, NOS3, NNMT | LMNA 3957/4885MAPK1 2097/4885ALDH1A1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.